Schweinfurthins and Uses Thereof

Neurofibromatosis type 1 (NF1) is a genetic disorder affecting 1 per 3000 individuals on average. Patients develop a variety of developmental benign and malignant pathologies. The most common tumors associated with NF1 are peripheral sheath tumors, including neurofibromas, optical gliomas, and malignant peripheral nerve sheath tumors.Researchers at the National Cancer Institute (NCI) developed novel analogs of the natural product schweinfurthin that inhibits growth of NF1-associated pathologies. The schweinfurthin analogs show inhibitory activity against mouse and human NF1 cancer cell lines. Glioma, diffuse B cell lymphoma, and leukemia cell lines also show significant sensitivity against the schweinfurthin analogs.  NIH Ref. No.: E-183-2009Advantages: Specificity of mode of action reduces potential side effects Novel mode of action Inhibitory activity against mouse and human NF1 cancer cell lineApplications: Therapies for tumors associated with NF1 Therapies for leukemia Therapies for diffuse B cell lymphomDevelopment Status: Discovery (Lead Identification)Updated On: Mar 20, 2018Provider Classifications: Date Published: Tuesday, December 5, 2017Publications: Patent Application: 10719562Patent Number: 8,686,016Licensing Contacts: Lead Inventor: Inventor Lab URL: https://ccr.cancer.gov/molecular-targets-program/john-a-beutlerhttps://ccr.cancer.gov/Pediatric-Oncology-Branch/karlyne-m-reillyLPM FIrst Name:&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research